Skip to main content
  1. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2020:gutjnl-2020-322539.
  2. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020;159:481-491.e3.
  3. Brenner EJ, Ungaro RC, Colombel JF, et al. IBD in the COVID-19 era: the value of international collaboration. Lancet Gastroenterol Hepatol 2020;5:887-888.
  4. Brenner EJ, Pigneur B, Focht G, et al. BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES. Clin Gastroenterol Hepatol 2020.
  5. Brenner EJ, Kappelman MD. Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020.
  6. Agrawal M, Brenner EJ, Zhang X et al. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis 2020.